Pharmaceutical company Midatech Pharma PLC (MTPH.LN) said Wednesday that it has signed a global licensing agreement with Novartis AG (NOVN.EB) for the oncology compound panobinostat.
The company intends to develop panobinostat for the treatment of brain tumor.
Shares at 0741 GMT trading 4.4% higher at 108 pence.
Write to Tapan Panchal at email@example.com
(END) Dow Jones Newswires
June 07, 2017 03:59 ET (07:59 GMT)